Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and ...
PRACT: a pragmatic randomized adaptive clinical trial protocol to investigate a culturally adapted brief negotiational intervention for alcohol use in the emergency department in Tanzania | Trials | Full Text
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV- BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Virology Research Clinic - University of Washington
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
UK volunteers to receive Moderna Omicron COVID-19 booster vaccine in clinical study | NIHR
Participants sought for COVID-19 vaccine trial for booster and variant protection
COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years | NEJM
Monitoring Visits in Clinical Trials
COVID-19 Boosters: Why You Should Schedule One Now
GCT to Perform Booster Visits in Russia
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with
Coronavirus (COVID-19) Vaccines | CardioSmart – American College of Cardiology
Department of Health and Social Care on Twitter: "Everyone aged 16 and over is eligible for the #COVID19 booster from three months after their second dose. Book an appointment online or find
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial - The Lancet
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial -
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study | Pediatric Research
NIH clinical trial evaluating mixed COVID-19 vaccine schedules begins | National Institutes of Health (NIH)
Coronavirus information
Looking beyond COVID-19 vaccine phase 3 trials | Nature Medicine
